Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADAG Adagene	$1.95 +1.6%	$1.71	$1.33 ▼ $3.58	$90.45M	0.74	61,241 shs	4,535 shs
COYA Coya Therapeutics	$5.51 +3.6%	$5.80	$4.65 ▼ $10.24	$88.98M	0.21	71,140 shs	46,605 shs
MIST Milestone Pharmaceuticals	$1.72 -0.6%	$1.34	$0.63 ▼ $2.75	$92.49M	0.92	932,153 shs	562,341 shs
MITO Stealth BioTherapeutics	$0.32	$0.32	$0.16 ▼ $1.03	$23.54M	1.46	946,105 shs	N/A

Reduce the Risk

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADAG Adagene	+1.56%	-1.52%	+10.17%	+9.55%	-25.29%
COYA Coya Therapeutics	+3.57%	-2.13%	-7.71%	-14.84%	-15.03%
MIST Milestone Pharmaceuticals	-0.58%	0.00%	+33.33%	-11.79%	+23.74%
MITO Stealth BioTherapeutics	0.00%	0.00%	0.00%	0.00%	0.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ADAG Adagene	2.5655 of 5 stars	3.3	5.0	0.0	0.0	0.0	1.7	0.0
COYA Coya Therapeutics	2.0831 of 5 stars	3.5	4.0	0.0	0.0	1.3	0.8	0.0
MIST Milestone Pharmaceuticals	2.1761 of 5 stars	3.2	3.0	0.0	0.0	1.9	2.5	0.0
MITO Stealth BioTherapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADAG Adagene	2.50	Moderate Buy	$8.00	310.26% Upside
COYA Coya Therapeutics	3.00	Buy	$16.67	202.48% Upside
MIST Milestone Pharmaceuticals	2.40	Hold	$7.00	306.98% Upside
MITO Stealth BioTherapeutics	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest MITO, MIST, ADAG, and COYA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/9/2025	COYA Coya Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$18.00
6/5/2025	MIST Milestone Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Buy	$5.00
5/13/2025	COYA Coya Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$14.00 ➝ $14.00
4/28/2025	COYA Coya Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$14.00 ➝ $14.00
4/22/2025	COYA Coya Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$18.00 ➝ $18.00
4/3/2025	ADAG Adagene	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$8.00 ➝ $8.00
4/1/2025	MIST Milestone Pharmaceuticals	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold
4/1/2025	MIST Milestone Pharmaceuticals	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
4/1/2025	MIST Milestone Pharmaceuticals	TD Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold
3/28/2025	MIST Milestone Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$25.00 ➝ $25.00
3/27/2025	COYA Coya Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$18.00 ➝ $18.00

(Data available from 6/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADAG Adagene	$100K	918.65	N/A	N/A	$1.14 per share	1.71
COYA Coya Therapeutics	$3.55M	25.97	N/A	N/A	$2.37 per share	2.32
MIST Milestone Pharmaceuticals	$1M	91.95	N/A	N/A	$0.25 per share	6.88
MITO Stealth BioTherapeutics	$21.09M	1.12	N/A	N/A	($0.79) per share	-0.41

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADAG Adagene	-$33.42M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	7/23/2025 (Estimated)
COYA Coya Therapeutics	-$14.88M	-$1.07	N/A	N/A	N/A	N/A	-48.88%	-43.32%	8/11/2025 (Estimated)
MIST Milestone Pharmaceuticals	-$41.52M	-$0.78	N/A	N/A	N/A	N/A	-329.85%	-67.20%	8/6/2025 (Estimated)
MITO Stealth BioTherapeutics	-$52.53M	-$0.52	N/A	N/A	N/A	N/A	N/A	-142.81%	N/A

Latest MITO, MIST, ADAG, and COYA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
5/14/2025	Q1 2025	MIST Milestone Pharmaceuticals	-$0.19	-$0.31	-$0.12	-$0.31	N/A	N/A
5/13/2025	Q1 2025	COYA Coya Therapeutics	-$0.44	-$0.44	N/A	-$0.44	$2.63 million	$257.88 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADAG Adagene	N/A	N/A	N/A	N/A	N/A
COYA Coya Therapeutics	N/A	N/A	N/A	N/A	N/A
MIST Milestone Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
MITO Stealth BioTherapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADAG Adagene	0.01	2.30	2.30
COYA Coya Therapeutics	N/A	8.84	8.84
MIST Milestone Pharmaceuticals	4.06	4.67	4.67
MITO Stealth BioTherapeutics	N/A	3.68	3.68

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADAG Adagene	9.51%
COYA Coya Therapeutics	39.75%
MIST Milestone Pharmaceuticals	86.18%
MITO Stealth BioTherapeutics	2.21%

Insider Ownership

Company	Insider Ownership
ADAG Adagene	21.20%
COYA Coya Therapeutics	12.00%
MIST Milestone Pharmaceuticals	19.50%
MITO Stealth BioTherapeutics	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADAG Adagene	260	47.11 million	37.12 million	Not Optionable
COYA Coya Therapeutics	6	16.73 million	14.72 million	Not Optionable
MIST Milestone Pharmaceuticals	30	53.46 million	43.04 million	Optionable
MITO Stealth BioTherapeutics	29	73.55 million	N/A	Not Optionable

MITO, MIST, ADAG, and COYA Headlines

Recent News About These Companies

'Hanging on by our fingernails': Stealth CEO questions efficiency behind FDA rejection of rare disease drug

May 31, 2025 | fiercebiotech.com

Stealth Cuts 30% of Workforce Following FDA Rejection, Still Eyes Barth Approval

May 30, 2025 | biospace.com

FDA rejects Stealth Bio’s Barth syndrome treatment after 16.5-month review

May 30, 2025 | msn.com

CRL blocks Barth syndrome drug; Stealth aims to try again

May 29, 2025 | bioworld.com

Stealth Bio confident, despite earlier FDA delays for elamipretide

May 29, 2025 | thepharmaletter.com

Stealth hit by FDA rejection to twice-delayed filing as it lays off staff

May 29, 2025 | fiercebiotech.com

Stealth Bio to cut jobs after FDA rejects therapy for rare disorder

May 29, 2025 | msn.com

US FDA asks Stealth BioTherapeutics to resubmit application for rare genetic condition therapy

May 29, 2025 | reuters.com

Post-Hoc: The big question for the FDA after Stealth’s PDUFA delay

May 5, 2025 | endpts.com

FDA misses decision deadline on Stealth’s Barth syndrome drug

April 30, 2025 | thepharmaletter.com

FDA Decision on Barth Syndrome Therapy Delayed Again

April 29, 2025 | empr.com

Amid FDA chaos, approval of a rare disease drug gets delayed — again

April 29, 2025 | statnews.com

FDA misses PDUFA date for Stealth’s ultra-rare disease candidate, delaying approval decision—again

April 29, 2025 | fiercebiotech.com

FDA misses approval deadline for biotech’s rare disease drug

April 29, 2025 | biopharmadive.com

FDA delays decision on Stealth BioTherapeutics' rare genetic disorder drug

April 29, 2025 | reuters.com

Stealth BioTherapeutics to Present New Bevemipretide Data at ARVO Annual Meeting

April 25, 2025 | oleantimesherald.com

Stealth BioTherapeutics reaches 50 percent enrollment target in phase 3 ReNEW study

March 17, 2025 | ophthalmologytimes.com

Stealth faces another hurdle as FDA delays decision on Barth syndrome drug

January 24, 2025 | msn.com

FDA delays decision on Stealth's 2nd shot at approval for ultrarare disease med

January 23, 2025 | fiercebiotech.com

Stealth BioTherapeutics Announces PDUFA Action Date Extension for Elamipretide to Treat Patients with Barth Syndrome

January 23, 2025 | prnewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

3 Defense Stocks That Will Profit From a Golden Dome
By Chris Markoch | May 30, 2025
View 3 Defense Stocks That Will Profit From a Golden Dome
Analysts Think These Stocks Could More Than Double in Value
By Nathan Reiff | May 23, 2025
View Analysts Think These Stocks Could More Than Double in Value
Intel’s Turnaround May Be the Best Bet No One’s Watching
By Jeffrey Neal Johnson | May 30, 2025
View Intel’s Turnaround May Be the Best Bet No One’s Watching
Don’t Take Dick’s Sporting Goods Seriously? Big Mistake
By Thomas Hughes | May 29, 2025
View Don’t Take Dick’s Sporting Goods Seriously? Big Mistake
GameStop Buys Bitcoin: Smart Strategy or Big Mistake?
By Thomas Hughes | May 28, 2025
View GameStop Buys Bitcoin: Smart Strategy or Big Mistake?

MITO, MIST, ADAG, and COYA Company Descriptions

Adagene NASDAQ:ADAG

$1.95 +0.03 (+1.56%)

Closing price 06/18/2025 03:56 PM Eastern

Extended Trading

$1.98 +0.03 (+1.54%)

As of 06/18/2025 04:59 PM Eastern

Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti- CD137 IgG4 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a masked fully-human anti-CTLA-4 mAb that is in Phase 1 clinical trial for the treatment advanced/metastatic solid tumors; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase 1b/2 clinical development for the treatment of advanced/metastatic solid tumors. It also offers ADG104, an anti-PD-L1 mAb that is in Phase 2 clinical development; ADG125, a novel anti-CSF-1R mAb, which is in Phase I clinical trial; ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is in preclinical for the treatment hematologic and solid tumors; ADG138, novel HER2xCD3 POWERbody, which is in preclinical for the treatment HER2-expressing solid tumors; and ADG152, a v POWERbody, which is in preclinical stage for the treatment off-tumor toxicities, as well as develops anti-CD28 bispecific POWERbody TCEs. The company was incorporated in 2011 and is headquartered in Suzhou, China.

Coya Therapeutics NASDAQ:COYA

$5.51 +0.19 (+3.57%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$5.61 +0.10 (+1.89%)

As of 06/18/2025 04:22 PM Eastern

Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. It is developing COYA 101, an autologous regulatory T-cell product candidate that has completed Phase 2a clinical trial for use in the treatment of Amyotrophic Lateral Sclerosis. The company's product candidates in IND-enabling studies include COYA 301, a low-dose interleukin 2 Treg-enhancing biologic, which is in Phase 2 clinical trial for use in the treatment of Frontotemporal Dementia; and COYA 302, a biologic combination for subcutaneous administration intended to enhance Treg function while depleting T effector function and activated macrophages for use in the treatment of neurodegenerative and autoimmune diseases. It is also developing COYA 201, an antigen directed Treg-derived exosome product candidate that is in preclinical stage for use in the treatment of neurodegenerative, autoimmune, and metabolic diseases; and COYA 206, an antigen directed Treg-derived exosome product candidate, which is in discovery stage. The company has a collaboration with Dr. Reddy's Laboratories SA for the development and commercialization of COYA 302, an investigational combination therapy for treatment of amyotrophic lateral sclerosis. The company was incorporated in 2020 and is headquartered in Houston, Texas.

Milestone Pharmaceuticals NASDAQ:MIST

$1.72 -0.01 (-0.58%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$1.72 0.00 (0.00%)

As of 06/18/2025 07:58 PM Eastern

Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans, as well as with the Montreal Heart Institute, the WCN network, and other research centers. The company was incorporated in 2003 and is headquartered in Montréal, Canada.

Stealth BioTherapeutics NASDAQ:MITO

Stealth BioTherapeutics Corp, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies for diseases involving mitochondrial dysfunction. Its lead product candidate is Elamipretide that is in phase 3 clinical trial to treat barth syndrome, phase 2/3 clinical trial for the treatment of duchenne cardiomyopathy, phase 2a clinical trial to treat friedreich's ataxia, phase 2 clinical trial for the treatment of dry age-related macular degeneration, phase 2 clinical trial to treat leber's hereditary optic neuropathy, and phase 3 clinical trial for the treatment of replisome myopathies. The company's product candidates also include SBT-20 to treat complications of diabetes, renal diseases, ocular diseases, neurodegenerative, Parkinson's, Alzheimer's, Huntington's, and ALS diseases; SBT-550 for rare neurological indications; and SBT-272, a peptidomimetic that targets the mitochondria and stabilizing mitochondrial function under conditions of oxidative stress, as well as SBT 550. Stealth BioTherapeutics Corp was incorporated in 2006 and is based in George Town, the Cayman Islands.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time